FindMyKOL
Clinical trialNCT02266745UnknownPhase 2Interventional

A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts

SponsorPromontory Therapeutics Inc.Enrollment109Advanced Solid TumorsCRPCGenital Neoplasms, MaleMetastatic Castrate-resistant Prostate CancerNeoplasms by SitePT-112+3 more conditions
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase 1/2, open-label, multi-center, non-randomized, dose-escalation study to be conducted in two parts: the Dose Escalation Phase and the Dose Expansion Phase. The Dose Escalation Phase will determine the Maximum Tolerated Dose (MTD) and recommended Phase 2 dose(s) (RP2D) of PT-112 Injection and evaluate its safety and tolerability, and PK (pharmacokinetics). The Dose Escalation Phase is complete and no longer enrolling. The Dose Expansion Phase has two cohorts: one cohort for the study of PT-112 in patients with thymoma and thymic carcinoma (Cohort A), and one cohort for the study of PT-112 in metastatic castrate-resistant prostate cancer (mCRPC) (Cohort D).
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

25 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

France
  • Besançon

    Besançon, France

  • Bordeaux

    Bordeaux, France

  • Caen

    Caen, France

  • Clermont-Ferrand

    Clermont-Ferrand, France

  • Marseille

    Marseille, France

  • Nice

    Nice, France

  • Paris

    Paris, France

  • Rennes

    Rennes, France

United States
  • Arizona

    Phoenix, Arizona, United States

  • Tucson

    Tucson, Arizona, United States

  • Duarte

    Duarte, California, United States

  • Colorado

    Aurora, Colorado, United States

  • Jacksonville

    Jacksonville, Florida, United States

  • Orlando

    Orlando, Florida, United States

  • Indianapolis

    Indianapolis, Indiana, United States

  • Boston

    Boston, Massachusetts, United States

  • Minneapolis

    Minneapolis, Minnesota, United States

  • Rochester

    Rochester, Minnesota, United States

  • Omaha

    Omaha, Nebraska, United States

  • Albuquerque

    Albuquerque, New Mexico, United States

  • Brooklyn

    Brooklyn, New York, United States

  • New York

    New York, New York, United States

  • Durham

    Durham, North Carolina, United States

  • University of Texas Md Anderson Cancer Center

    Houston, Texas, United States

  • Seattle

    Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PT-112 Injection
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Jul 2014
Primary completion
1 Aug 2024
Completion
1 Apr 2025
Last update posted
5 Apr 2024
Registered enrollment
109
Registry id
NCT02266745
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.